Pamidronate Disodium (Aredia®)

Common name: Pamidronate Disodium
Brand name: Aredia®
 

What is Pamidronate Disodium?

Pamidronate Disodium belongs to the bisphosphonate class of drugs that is used to treat osteoporosis (bone thinning). It works by reducing the breakdown of bone.


How is Pamidronate Disodium administered?

Pamidronate disodium is administered intravenously.
 

What are possible side effects of this treatment?

Everyone responds differently to treatments for bone metastases – some experience many side effects while others experience very few. Below are some side effects experienced by those who received pamidronate disodium. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Abdominal pain
  • Bone pain
  • Difficulty sleeping
  • Headache
  • Loss of appetite
  • Nausea / vomiting
  • Weakness
 

Is Pamidronate Disodium covered in my province or territory?*

Pamidronate disodium is covered by provincial drug programs in:
  • Alberta
  • British Columbia
  • Manitoba
  • Northwest Territories
  • Nunavut
  • Ontario
  • Prince Edward Island
  • Quebec
  • Saskatchewan
  • Yukon
Pamidronate Disodium is not covered by provincial drug programs in:
  • New Brunswick
  • Newfoundland & Labrador
  • Nova Scotia

*Source: http://drugcoverage.ca/en-ca/search-results.aspx?ID=9766

Last Reviewed: July 2017

Help us take the first steps toward prevention. Donate Now




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Do men’s toenails contain clues about prostate cancer prevention?

Toronto, January 29, 2018 – Funded by Prostate Cancer Canada (PCC), Dr.
More

Discovery of a promising new medication to block 'master key' of cancer growth

Vancouver, BC – For years, researchers have investigated approaches to prevent cancer-causing cells from multiplying in the body.
More

RFP: Content Development and Delivery of an Accredited Electronic Continuing Medical Education Course for Prostate Cancer Specialists

Prostate Cancer Canada invites applications from service providers interested in the development, promotion and delivery of an accredited electronic Continuing Medical Education course targeting prostate cancer specialists, including urologists.
More


Click here for news archive